Stay updated with breaking news from Mutation Panel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced signing
Adoption of innovative testing strategies like mutation panels will enable government and healthcare bodies to not only manage the pandemic but also empower laboratories to abet such outbreaks in the future
Thermo Fisher Scientific , the world leader in serving science, has announced it has updated its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to detect the Delta and Lambda strains. First launched in March 2021, the research panel features a customizable menu of verified real-time PCR assays for identification of SARS-CoV-2 mutations.
Published: Apr 07, 2021 - Program Powered by Applied DNA’s Mutation-targeted qPCR Assays and NGS Platform - - Program Data Potentially Relevant to COVID-19 Vaccine and Therapeutics Developers, Precision Medicine - STONY BROOK & NEW HYDE PARK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences, Inc.. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and Northwell Health (Northwell) today announced their entry into a pro bono Material Transfer Agreement (MTA) that establishes a real-time surveillance program for the...
Product News: Thermo Fisher Scientific launches panel to monitor for COVID-19 mutations Panel designed to provide surveillance of ongoing mutations of virus that causes COVID-19 12 Mar 2021 Thermo Fisher Scientific, a world leader in serving science, has announced the launch of its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel, a customizable menu of 22 verified real-time PCR assays for identification of SARS-CoV-2 mutations. These assays enable surveillance of variants that are causing COVID-19 infections in specific regions globally and allow laboratories to choose which mutations to ...